Fulcrum Therapeutics Inc Stock News

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Fulcrum Therapeutics said on Monday it would merge with privately held Slate Medicines in an all-stock deal, as ​the biotech looks to rebuild its pipeline after it ‌discontinued development of its lead drug candidate last month.

Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics

SEC filings reflected insider equity holdings and awards totaling more than 264,000 shares NEW YORK, June 3, 2026 /PRNewswire/ -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) lost approximately 50% of its value in a single session after disclosing on June 1, 2026, that the FDA had raised class-wide safety concerns about PRC2-targeting agents, leading the Company to discontinue the program of its l...

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Fulcrum Therapeutics, Inc. (NASDAQ: FULC) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) (NASDAQ: FULC) complied with federal securities laws. On June 1, 2026, Fulcrum announced the discontinuation of its pociredir program for the treatment of sickle cell disease. The price of the Company's stock dropped following this news.

Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following cancer-risk ​concerns raised by the U.S. FDA, and explore strategic options ‌including a potential sale or merger.

Fulcrum Therapeutics said on Monday it would stop developing its experimental sickle-cell disease drug after the ​U.S. Food and Drug Administration raised cancer-risk ‌concerns, which left no viable regulatory path for the treatment.